Interesting post from Michaels. In biotech, there is always research and development going on for various diseases and conditions. There is NEVER a time in biotech when there is only ONE company working on something.
Just an observation and an opinion here. Michaels was subtly trying to inform the public that the valuations commanded by companies working in the same area as CUBT are significantly higher than the current market cap.
There is no way to compare apples to apples, because each situation is different.
CUBT could have positive results from the Metformin eye drop trials that raises the company's profile to attract a partner or more.
A PRV for the rabies drug alone could be monetized for over $100 million. No way of knowing if or when. But the potential is there.
Covid vaccine adjunct? Huge possibilities -- and worth nothing in the stock price right now.
Never fun to see tax loss selling hit a stock so hard on so little volume.
I had a GTC order to buy at $0.05 that I really did not think I would get, but I did today.
GLTA--January is coming soon.
News 
Market Data 
Discover 
AI
